Ideaya Biosciences, Inc. (IDYA) Stock Price & Analysis
Ideaya Biosciences, Inc. (IDYA) fell 2.29% to USD 35.4 as of July 25, 2026 at 03:47 UTC, according to Nexqual real-time market data.
IDYA last closed at USD 36.23; the session ranged USD 35.28–37.9 on volume of 882,792 shares. Market capitalization is $3.41B, with a 52-week range of USD 22.09–40.58 (NMS). Source: Nexqual, July 25, 2026 at 03:47 UTC.
Key Statistics (as of July 25, 2026 at 03:47 UTC)
| Price | USD 35.4 |
|---|---|
| Change | ▼ 2.29% (down) |
| Previous Close | USD 36.23 |
| Open | USD 37.9 |
| Day Range | USD 35.28 – 37.9 |
| 52-Week Range | USD 22.09 – 40.58 |
| Volume | 882,792 shares |
| Market Cap | $3.41B |
| Exchange | NMS |
Technical Analysis (IDYA)
Nexqual's technical model rates IDYA "NEUTRAL" based on 3 bullish and 2 bearish signals across 125 daily candles, as of July 25, 2026 at 03:47 UTC.
| Overall Signal | NEUTRAL |
|---|---|
| RSI (14) | 53.33 (neutral) |
| vs SMA50 | Above (USD 32.74) |
| MACD | 0.68 (positive) |
Analyst Ratings (IDYA)
Wall Street analysts rate IDYA "Strong Buy" based on 13 analysts, with a mean price target of USD 53.54 (range USD 37–66), per Nexqual as of July 25, 2026 at 03:47 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 13 |
| Mean Target | USD 53.54 |
| High Target | USD 66 |
| Low Target | USD 37 |
| Buy / Hold / Sell | 14 / 1 / 0 |
Earnings (IDYA)
| Next Earnings Date | 2026-08-10 |
|---|---|
| EPS Estimate | USD -1.06 |
| Revenue Estimate | $7.45M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -1.11 vs est -0.98 ▼ miss |
| 2025-12-31 | USD -0.94 vs est -0.95 ▲ beat |
| 2025-09-30 | USD 1.33 vs est -0.55 ▲ beat |
| 2025-06-30 | USD -0.88 vs est -0.79 ▼ miss |
Source: Nexqual, July 25, 2026 at 03:47 UTC.
Financials & Fundamentals (IDYA)
| Total Revenue | $225.27M |
|---|---|
| Gross Margin | -50.73% |
| Operating Margin | -1654.63% |
| Profit Margin | -62.17% |
| ROE | -14.28% |
| Debt / Equity | 3.05 |
| Current Ratio | 10.74 |
| Total Cash | $671.20M |
| Total Debt | $28.60M |
| Free Cash Flow | $-57.25M |
Source: Nexqual, July 25, 2026 at 03:47 UTC.
Financial Health Score (IDYA)
Nexqual rates Ideaya Biosciences, Inc.'s overall financial health "Weak" across five dimensions, as of July 25, 2026 at 03:47 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $671M cash vs $29M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$57M, burning cash |
| Efficiency | Critical — ROE -14%, ROA -10.8% |
Ownership (IDYA)
| Insider Ownership | +2.22% |
|---|---|
| Institutional Ownership | +101.86% |
| Shares Outstanding | 96.27M |
| Float | 87.08M |
| Short % of Float | +12.47% |
Source: Nexqual, July 25, 2026 at 03:47 UTC.
Leadership (IDYA)
Ideaya Biosciences, Inc. is led by Yujiro S. Hata (age 51), Founder, President, CEO & Chairman, per Nexqual as of July 25, 2026 at 03:47 UTC.
| Founder, President, CEO & Chairman | Yujiro S. Hata (age 51) |
|---|---|
| Chief Scientific Officer | Michael A. White (age 60) |
| Chief Technology Officer | Paul A. Barsanti |
| Senior Vice President of Medical Writing & Project Management | Mick O'Quigley |
Major Backers & Investors (IDYA)
Notable institutional backers of Ideaya Biosciences, Inc. include FMR, LLC, Janus Henderson Group PLC, Fidelity, according to Nexqual as of July 25, 2026 at 03:47 UTC.
Active Investors
| Investor | Stake |
|---|---|
| FMR, LLC | 14.99% |
| Janus Henderson Group PLC | 8.27% |
| Fidelity | 7.46% |
| Capital Group | 5.88% |
| SmallCap World Fund Inc | 5.33% |
| Baker Bros. Advisors, LP | 4.49% |
| Federated Hermes, Inc. | 4.4% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 11.92% |
| Vanguard Group | 8.4% |
| State Street | 6.92% |
Source: Nexqual, July 25, 2026 at 03:47 UTC.
From Ideaya Biosciences, Inc.'s Latest SEC 10-K Filing (filed 2026-02-17)
Key Strengths & Strategy (as disclosed to the SEC)
- IDEAYA Biosciences, Inc., a precision medicine oncology company, develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States.
- The company offers Darovasertib, an oral, potent, and selective protein kinase, C (PKC) inhibitor for the treatment of uveal melanoma, ocular cancer, and is being evaluated in multiple clinical trials as monotherapy and in combination with crizotinib for metastatic, neoadjuvant, and adjuvant settings.
- In addition, the company offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform.
- The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Gilead Sciences, Inc., Novartis, Biocytogen, Cancer Research UK, the University of Manchester, Jiangsu Hengrui Pharmaceuticals Co., Ltd., and Les Laboratoires Servie.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| CRNX | Crinetics Pharmaceuticals, Inc. | USD 83.73 | ▲ 0.01% |
| BCYC | Bicycle Therapeutics plc | USD 3.87 | ▼ 8.08% |
| KYMR | Kymera Therapeutics, Inc. | USD 110.57 | ▲ 0.21% |
| PCVX | Vaxcyte, Inc. | USD 54.66 | ▼ 2.39% |
| MIRM | Mirum Pharmaceuticals, Inc. | USD 113.03 | ▼ 1.27% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 03:47 UTC. This page is informational and not investment advice.